Radiomics in Hepatology: Therapeutic Applications in Hepatocellular Carcinoma.
Imaging is essential in hepatocellular carcinoma (HCC) management, from screening to treatment assessment, but qualitative methods have limitations.
APA
Kim TH, Do RKG, et al. (2025). Radiomics in Hepatology: Therapeutic Applications in Hepatocellular Carcinoma.. Clinics in liver disease, 29(4), 717-741. https://doi.org/10.1016/j.cld.2025.06.004
MLA
Kim TH, et al.. "Radiomics in Hepatology: Therapeutic Applications in Hepatocellular Carcinoma.." Clinics in liver disease, vol. 29, no. 4, 2025, pp. 717-741.
PMID
41109699
Abstract
Imaging is essential in hepatocellular carcinoma (HCC) management, from screening to treatment assessment, but qualitative methods have limitations. Radiomics, a quantitative imaging approach, extracts high-dimensional features to enhance diagnostic, prognostic, and therapeutic decision-making. It shows promise in predicting treatment response and guiding personalized therapies. Integrating radiomics with artificial intelligence, particularly deep learning, could further improve predictive accuracy and clinical utility. Future efforts should focus on standardization, validation, and developing accessible tools to incorporate radiomics into routine therapeutic strategies, ultimately optimizing patient outcomes in HCC.
MeSH Terms
Humans; Carcinoma, Hepatocellular; Liver Neoplasms; Artificial Intelligence; Deep Learning; Prognosis; Radiomics
같은 제1저자의 인용 많은 논문 (5)
- Cancer-associated fibroblast-derived GAS6 increases resistance to chemotherapy through AXL/STAT3/ABCG1 in gastric cancer.
- Bridging the Gap between Microsurgery and Supermicrosurgy: A Rat Study for 0.3 mm Vascular Anastomosis Comparing a Robotic-assisted vs. Conventional Approach.
- Efficacy and Safety of LetibotulinumtoxinA Injection for Trapezius Hypertrophy: A Prospective, Randomized, Double-Blind Trial.
- Metabolic crosstalk among cancer-associated fibroblasts, adipocytes and immune cells as an immunosuppressive tumor microenvironment driver.
- How I Do It: Systemic Therapies for Primary Liver Cancers.